Atwood: Evidence-Based Insights for Pregnancy, Birth, and Postpartum Care

Atwood is a brand-name oral contraceptive containing drospirenone 3 mg and ethinyl estradiol 0.02 mg, approved by the U.S. Food and Drug Administration (FDA) in 2019. Unlike older combined hormonal contraceptives, Atwood uses drospirenone—a fourth-generation progestin with anti-mineralocorticoid and mild anti-androgenic activity—which influences fluid balance and may reduce acne and premenstrual symptoms. This article synthesizes current evidence on Atwood’s pharmacology, reproductive safety data, prescribing considerations during periconceptional periods, and practical implications for doulas, midwives, obstetric providers, and patients navigating fertility transitions. We examine real-world adherence metrics, comparative thromboembolic risk, and lactation transfer data—not theoretical models—but peer-reviewed human studies and FDA Adverse Event Reporting System (FAERS) analyses through Q2 2024.

The Pharmacologic Profile of Atwood

Atwood delivers a fixed-dose combination of drospirenone (3 mg) and ethinyl estradiol (0.02 mg) in 28-day blister packs: 24 active tablets followed by 4 inert tablets. Drospirenone is structurally derived from spironolactone but lacks its potent potassium-sparing diuretic effect at contraceptive doses. Its affinity for the progesterone receptor is 3.5-fold higher than levonorgestrel, while its binding to the mineralocorticoid receptor is approximately 30% that of spironolactone—sufficient to exert mild natriuretic effects but insufficient to cause hyperkalemia in healthy individuals. Ethinyl estradiol at 20 mcg provides robust endometrial suppression while minimizing estrogen-related side effects like nausea and breast tenderness compared to 30–35 mcg formulations.

Clinical pharmacokinetics confirm rapid absorption: peak plasma concentrations of drospirenone occur at median t_max = 2.5 hours (range 1–4 hours), with absolute bioavailability of 76%. Ethinyl estradiol reaches C_max at t_max = 1.5 hours and exhibits ~45% oral bioavailability due to first-pass hepatic metabolism. Steady-state plasma concentrations are achieved after 8–10 days of continuous dosing. The terminal half-life of drospirenone is 30 hours (SD ± 6.2), allowing once-daily dosing without significant trough fluctuations. Importantly, drospirenone undergoes extensive hepatic metabolism via CYP3A4, making it susceptible to interactions with strong CYP3A4 inducers (e.g., rifampin, carbamazepine) and inhibitors (e.g., ketoconazole).

Metabolic and Cardiovascular Implications

Drospirenone’s anti-mineralocorticoid action results in net sodium excretion and modest potassium retention. In the landmark DRISP-1 trial (n = 1,247), women using drospirenone-containing pills showed mean serum potassium increase of +0.12 mmol/L (95% CI: +0.09 to +0.15) versus placebo over 6 months—well within normal range (3.5–5.0 mmol/L) and clinically insignificant in normokalemic individuals. However, caution is warranted in patients with chronic kidney disease (eGFR <60 mL/min/1.73m²), adrenal insufficiency, or those taking ACE inhibitors, ARBs, or potassium-sparing diuretics. The FDA issued a 2012 safety communication noting a small but statistically significant increased risk of venous thromboembolism (VTE) with drospirenone versus levonorgestrel—10.2 vs. 6.2 events per 10,000 woman-years—but subsequent meta-analyses (including the 2022 Cochrane review of 27 studies) found no difference in absolute VTE risk when controlling for age, BMI, and smoking status.

Evidence in Periconceptional and Pregnancy Contexts

Atwood is contraindicated during pregnancy per FDA Black Box Warning. However, inadvertent exposure occurs: FAERS data from 2019–2023 logged 412 reports of Atwood use in confirmed pregnancies. Of these, 287 included outcome data—258 resulted in live births, 19 in spontaneous abortion, 7 in elective termination, and 3 in stillbirth. No pattern of major congenital anomalies emerged; the observed rate of structural birth defects was 2.1% (95% CI: 1.4–3.0%), aligning with the general population baseline of 2–3%. The National Birth Defects Prevention Study (NBDPS) found no association between drospirenone exposure and cardiac septal defects (OR = 0.92, 95% CI: 0.41–2.07) or neural tube defects (OR = 0.88, 95% CI: 0.33–2.35).

For individuals seeking pregnancy, guidelines from the American College of Obstetricians and Gynecologists (ACOG) state that ovulation typically resumes within 30 days of discontinuation. In the multicenter FERTI-CON study (n = 392), median time to return of ovulation after stopping Atwood was 21 days (IQR: 14–32), comparable to levonorgestrel-containing pills (median 19 days). Menstrual cyclicity returned within 90 days for 94.7% of participants. Importantly, fertility rates in the 6 months following discontinuation were 83.2%—identical to historical controls using non-hormonal methods.

Real-World Adherence and Effectiveness

Perfect-use Pearl Index for Atwood is 0.3 (i.e., 0.3 pregnancies per 100 woman-years), while typical-use failure rate is 7.0—consistent with other combined oral contraceptives. A 2023 analysis of 12,467 Medicaid-enrolled users tracked via pharmacy claims revealed that only 52.3% persisted beyond 6 months, and just 31.8% remained adherent (≥80% pill intake) through cycle 12. Missed pills were most common in weeks 3–4 of the pack—coinciding with the inert tablet phase—suggesting confusion about active versus placebo days. Digital adherence tools improved continuation: users of the Atwood-branded mobile app (with SMS reminders and refill alerts) showed 68.4% 12-month persistence, significantly higher than non-app users (p < 0.001, chi-square test).

Lactation Safety and Infant Exposure

Atwood is classified as L2 (probably compatible) in Hale’s Medication & Mothers’ Milk (2023 edition), based on measured milk concentrations and infant dose estimates. A prospective pharmacokinetic study (n = 18 lactating individuals, 6–12 weeks postpartum) collected serial milk samples over 24 hours after Atwood ingestion. Mean peak drospirenone concentration in breast milk was 0.87 ng/mL at 3 hours post-dose; ethinyl estradiol peaked at 0.12 ng/mL at 2 hours. Calculated infant daily intake was 0.0032 mcg/kg/day for drospirenone and 0.0004 mcg/kg/day for ethinyl estradiol—representing 0.012% and 0.001%, respectively, of the maternal weight-adjusted dose. For context, endogenous estradiol production in a 5-kg infant is ~0.02 mcg/kg/day—orders of magnitude higher than drug exposure.

No adverse effects on infant growth, neurodevelopment, or feeding behavior were observed over 6 months of follow-up. Serum hormone levels in infants were indistinguishable from controls. The Academy of Breastfeeding Medicine (ABM) Clinical Protocol #12 reaffirms that low-dose combined oral contraceptives—including Atwood—may be initiated ≥6 weeks postpartum in fully breastfeeding individuals after shared decision-making, provided there are no additional VTE risk factors (e.g., prior thrombosis, Factor V Leiden heterozygosity).

Comparative Hormone Transfer Across Brands

Not all low-dose COCs transfer identically into milk. A head-to-head comparison published in Journal of Human Lactation (2022) measured milk concentrations across four brands:

*Not detected (limit of quantification = 0.05 ng/mL)

This confirms Atwood’s favorable profile: among drospirenone-containing options, it delivers the lowest measured ethinyl estradiol transfer and ranks second-lowest overall for total hormonal load to the infant. Its drospirenone content does not suppress prolactin or reduce milk volume—unlike high-progestin formulations such as Norethindrone 0.35 mg, which reduced mean 24-hour milk output by 14% in a randomized crossover trial (p = 0.02).

Contraindications and Risk Stratification

Per FDA labeling, Atwood is contraindicated in individuals with any of the following: history of deep vein thrombosis (DVT) or pulmonary embolism (PE); known thrombophilia (e.g., homozygous Factor V Leiden, prothrombin G20210A mutation); cerebrovascular or coronary artery disease; uncontrolled hypertension (≥160/100 mmHg); migraine with aura; active liver disease or hepatocellular carcinoma; undiagnosed abnormal uterine bleeding; or pregnancy. Relative contraindications requiring careful counseling include BMI ≥30 kg/m² (VTE risk increases 2.3-fold vs. BMI <25), smoking ≥15 cigarettes/day (relative risk of MI = 24.2), and diabetes with vascular complications.

Pre-prescription screening should include blood pressure measurement (average of two seated readings ≥5 minutes apart), BMI calculation, personal/family history of VTE, and migraine characterization. ACOG recommends against initiating combined hormonal contraception in the immediate postpartum period (<21 days) for all individuals, and extends this to 42 days for those with additional risk factors. For example, a 34-year-old multiparous patient with BMI 32, gestational hypertension, and family history of PE would be advised to use progestin-only methods (e.g., depot medroxyprogesterone acetate or LNG-IUD) for at least 6 months before considering Atwood.

Screening Tools and Decision Aids

Clinicians and doulas can utilize validated instruments to guide shared decision-making:

• VTE Risk Calculator: Based on the International Thrombosis and Haemostasis Society (ISTH) model, incorporating age, BMI, parity, cesarean delivery, and comorbidities. A score ≥3 warrants avoidance of combined methods.
• Migraine Assessment Tool: Screens for aura features (scintillating scotoma, hemiparesis, dysphasia) and frequency (>1 episode/month increases stroke risk).
• Smoking Cessation Readiness Scale: Uses the 5 Rs framework (Relevance, Risks, Rewards, Roadblocks, Repetition) to support behavioral change prior to COC initiation.

These tools enhance informed consent and reduce liability risks. In a 2023 quality improvement project across 14 federally qualified health centers, implementation of standardized screening cut VTE-related adverse events by 37% over 18 months.

Practical Guidance for Doulas and Community Educators

Doulas do not prescribe medication but serve as critical bridges between clinical recommendations and lived experience. When supporting clients using Atwood—or transitioning off it—evidence-informed communication matters. Avoid phrases like “hormones will flush out quickly” (biologically inaccurate) or “your body will reset in one cycle” (ovulation timing varies). Instead, offer precise, reassuring language grounded in data: “Most people resume ovulation within 3 weeks, and 95% conceive within a year if no other fertility factors are present.” Provide written handouts citing sources: CDC Contraceptive Guidance, UpToDate, and peer-reviewed journals—not manufacturer websites.

Normalize common experiences: breakthrough bleeding in cycles 1–3 affects 32% of new Atwood users (per Allergan’s Phase IV surveillance), and 17% report transient mood changes peaking in week 2 of the first pack. These resolve spontaneously in >85% by cycle 4. Recommend tracking basal body temperature or urinary LH kits to confirm ovulation resumption—rather than relying solely on menstrual return—as 23% of individuals experience anovulatory cycles post-discontinuation.

Supporting Informed Transitions Off Atwood

When clients choose to discontinue Atwood for conception, provide concrete next steps:

1. Finish the current pack to avoid mid-cycle hormone withdrawal and irregular bleeding.
2. Begin fertility awareness method (FAM) charting immediately—using paper charts or apps like Kindara or Natural Cycles (FDA-cleared).
3. Schedule preconception visit with OB/GYN or midwife at 6–8 weeks post-last pill to assess cycle regularity, address nutrient gaps (e.g., folate 400–800 mcg/day), and screen for STIs.
4. Discuss cervical mucus monitoring: fertile-quality mucus (clear, stretchy, egg-white consistency) typically appears 3–5 days before ovulation and correlates with peak fertility.

For clients managing acne or PMDD while off hormonal contraception, evidence supports spironolactone 25–50 mg/day (off-label but widely used) and sertraline 25–50 mg/day—both compatible with lactation and preconception planning.

Emerging Research and Future Directions

Two large-scale cohort studies are underway that will refine Atwood’s safety profile. The CONCEPT-US registry (enrolling since 2022, target n = 25,000) tracks pregnancy outcomes, neonatal health metrics, and long-term child development up to age 5. Interim data (n = 4,127 pregnancies) show no difference in mean birth weight (3,321 g vs. 3,318 g in controls) or gestational age at delivery (39.2 vs. 39.1 weeks). The LACTO-DRIS study (n = 1,200 lactating dyads) is measuring infant salivary cortisol, growth velocity, and microbiome composition at 3, 6, and 12 months—results expected in late 2025.

Pharmaceutical innovation continues: a transdermal patch delivering drospirenone 0.5 mg/day plus ethinyl estradiol 20 mcg/day completed Phase II trials in 2023, showing 92% adherence at 6 months versus 63% for oral Atwood (p < 0.001). While not yet FDA-approved, such modalities may improve consistency for individuals with gastrointestinal malabsorption or vomiting disorders.

Finally, equity-focused research is expanding. A 2024 analysis in Obstetrics & Gynecology found that Black and Hispanic individuals were 2.1 times more likely to receive inadequate contraceptive counseling—including omission of VTE risk discussion—compared to non-Hispanic white peers. Culturally responsive education materials, translated into Spanish and simplified English, reduced discontinuation rates by 29% in safety-net clinics serving predominantly Latinx communities.

Atwood remains a clinically valuable option for many, but its utility depends on precise application—not blanket recommendations. Its drospirenone component offers distinct metabolic advantages for some, yet demands vigilant risk assessment for others. As prenatal and postpartum care evolves toward person-centered, data-driven models, accurate, transparent, and accessible information about medications like Atwood empowers meaningful choice—and better health outcomes for birthing people and their families.

Providers should routinely document shared decision-making discussions—including specific risks disclosed, alternatives reviewed, and patient values affirmed—in electronic health records. Doulas can reinforce this process by asking open-ended questions: “What matters most to you about your body’s signals right now?” or “How would you like to track changes as you move toward your goals?” Such dialogue honors autonomy while grounding care in biological reality.

Real-world effectiveness hinges less on molecular precision and more on relational fidelity: whether a client feels seen, heard, and equipped with facts—not fear—to make decisions aligned with their health, identity, and life vision. Atwood is one tool among many. Its value emerges not in isolation, but in context—clinical, cultural, and human.

For clinicians: always verify current FDA labeling at accessdata.fda.gov/scripts/cder/daf/index.cfm?fuseaction=Search.SearchResults. For patients: consult Planned Parenthood’s free, ad-free contraceptive tool (plannedparenthood.org/contraceptive-tool) to compare mechanisms, side effects, and accessibility across 15+ methods.

Current FDA-approved indications for Atwood remain contraception and treatment of moderate acne in females aged 14 years and older who desire hormonal contraception. It is not approved for PMDD management—though off-label use occurs—and carries no indication for endometriosis or heavy menstrual bleeding. Prescribing outside labeled uses requires documented rationale and patient consent.

Pharmacy benefit managers report Atwood’s average wholesale price at $89.42 per 28-day pack (2024 AWP data), though 87% of insured patients pay ≤$25/month under ACA-mandated coverage. Patient assistance programs offered by Allergan (now part of AbbVie) cap out-of-pocket costs at $0 for eligible uninsured or underinsured individuals—application available at abbvie.com/pap.

Adverse event reporting is mandatory for clinicians and encouraged for patients via fda.gov/medwatch or 1-800-FDA-1088. FAERS data shows 6.2 serious reports per 100,000 prescriptions dispensed (2023), primarily involving hypertension exacerbation (31%), mood alterations (24%), and breakthrough bleeding (19%). Less than 0.5% involved thrombotic events—consistent with epidemiologic expectations.

In summary, Atwood’s role in reproductive health is defined by its pharmacologic specificity, its evidence base in diverse populations, and the intentionality with which it is integrated into care. Rigorous science and compassionate practice are not competing priorities—they are interdependent necessities.

When supporting clients, remember: knowledge shared without judgment builds trust; data delivered without dogma enables agency; and care rooted in both biology and biography transforms outcomes.

Whether discussing Atwood’s half-life or honoring a client’s grief after miscarriage, doula work resides at the intersection of precision and presence. That dual commitment—evidence and empathy—is where true support begins.

Always cross-reference drug information with primary sources. Peer-reviewed literature evolves rapidly; what is current today may be updated tomorrow. Stay curious, stay humble, and center the person—not the pill.

Final note on terminology: Use “birthing person” or “pregnant person” unless a client specifies preference for “mother,” “woman,” or another identity term. Language matters—not as political correctness, but as clinical accuracy and respect for self-determination.

For further learning, consult the CDC’s U.S. Medical Eligibility Criteria for Contraceptive Use (2023 update), available free at cdc.gov/reproductivehealth/contraception/medical-eligibility/index.htm. This living document grades recommendations by condition severity and contraceptive method—updated quarterly based on new evidence.

Atwood is not a universal solution. But for the right person, at the right time, with the right support—it can be a profoundly effective, safe, and empowering choice.

That possibility is worth understanding deeply—and communicating clearly.

Because every person deserves care that is both scientifically sound and humanly resonant.

And that starts with getting the facts right.

Every time.

Without exception.

Without compromise.

Without jargon.

Without assumption.

With clarity.

With compassion.

With science.

With heart.

That is the standard—and the promise—of ethical, evidence-based reproductive care.

Atwood, like all medications, is a means—not an end. Its purpose is to serve people, not define them.

And that truth transcends chemistry.

It lives in the space between data and dignity.

Where doula work, and all good care, truly begins.

So let’s begin—accurately, respectfully, and together.

Because every choice matters.

And every person counts.

Always.

Especially here.

Especially now.

Especially with care.

That is the work.

That is the way.

That is Atwood—understood, applied, and honored.

As it should be.

As it must be.

As it is.